vs
Side-by-side financial comparison of Axos Financial, Inc. (AX) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $392.2M, roughly 1.6× Axos Financial, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 31.8%, a 2.7% gap on every dollar of revenue. Over the past eight quarters, Axos Financial, Inc.'s revenue compounded faster (16.1% CAGR vs 4.6%).
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
AX vs RPRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $392.2M | $622.0M |
| Net Profit | $124.7M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | — | 62.4% |
| Net Margin | 31.8% | 34.4% |
| Revenue YoY | — | 4.8% |
| Net Profit YoY | 18.5% | 2.9% |
| EPS (diluted) | $2.15 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $622.0M | ||
| Q3 25 | $323.4M | $609.3M | ||
| Q2 25 | $321.4M | $578.7M | ||
| Q1 25 | $308.8M | $568.2M | ||
| Q4 24 | $307.9M | $593.6M | ||
| Q3 24 | $320.7M | $564.7M | ||
| Q2 24 | $290.9M | $537.3M |
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $214.2M | ||
| Q3 25 | $112.4M | $288.2M | ||
| Q2 25 | $110.7M | $30.2M | ||
| Q1 25 | $105.2M | $238.3M | ||
| Q4 24 | $104.7M | $208.2M | ||
| Q3 24 | $112.3M | $544.0M | ||
| Q2 24 | $104.9M | $102.0M |
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 62.4% | ||
| Q3 25 | 46.3% | 70.1% | ||
| Q2 25 | 48.5% | 36.3% | ||
| Q1 25 | 47.9% | 94.0% | ||
| Q4 24 | 48.8% | 60.9% | ||
| Q3 24 | 49.6% | — | ||
| Q2 24 | 49.6% | 50.2% |
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | 34.4% | ||
| Q3 25 | 34.7% | 47.3% | ||
| Q2 25 | 34.4% | 5.2% | ||
| Q1 25 | 34.1% | 41.9% | ||
| Q4 24 | 34.0% | 35.1% | ||
| Q3 24 | 35.0% | 96.3% | ||
| Q2 24 | 36.0% | 19.0% |
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $0.49 | ||
| Q3 25 | $1.94 | $0.67 | ||
| Q2 25 | $1.89 | $0.07 | ||
| Q1 25 | $1.81 | $0.55 | ||
| Q4 24 | $1.80 | $0.46 | ||
| Q3 24 | $1.93 | $1.21 | ||
| Q2 24 | $1.75 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $3.1B | $9.7B |
| Total Assets | $29.2B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $618.7M | ||
| Q3 25 | $2.6B | $938.9M | ||
| Q2 25 | $1.9B | $631.9M | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.4B | $929.0M | ||
| Q3 24 | $2.6B | $950.1M | ||
| Q2 24 | $2.0B | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | $312.7M | $8.0B | ||
| Q1 25 | $377.4M | $7.6B | ||
| Q4 24 | $358.7M | $7.6B | ||
| Q3 24 | $313.5M | $7.6B | ||
| Q2 24 | $325.7M | $7.6B |
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $9.7B | ||
| Q3 25 | $2.8B | $9.6B | ||
| Q2 25 | $2.7B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.5B | $10.3B | ||
| Q3 24 | $2.4B | $10.3B | ||
| Q2 24 | $2.3B | $9.8B |
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $19.6B | ||
| Q3 25 | $27.4B | $19.3B | ||
| Q2 25 | $24.8B | $18.3B | ||
| Q1 25 | $24.0B | $17.6B | ||
| Q4 24 | $23.7B | $18.2B | ||
| Q3 24 | $23.6B | $18.0B | ||
| Q2 24 | $22.9B | $17.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | 0.12× | 0.84× | ||
| Q1 25 | 0.14× | 0.78× | ||
| Q4 24 | 0.14× | 0.74× | ||
| Q3 24 | 0.13× | 0.74× | ||
| Q2 24 | 0.14× | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $827.1M | ||
| Q3 25 | $118.4M | $702.6M | ||
| Q2 25 | $490.3M | $364.0M | ||
| Q1 25 | $73.7M | $596.1M | ||
| Q4 24 | $162.5M | $742.5M | ||
| Q3 24 | $70.8M | $703.6M | ||
| Q2 24 | $305.5M | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | — | ||
| Q3 25 | $109.3M | — | ||
| Q2 25 | $436.1M | — | ||
| Q1 25 | $65.1M | — | ||
| Q4 24 | $156.4M | — | ||
| Q3 24 | $53.0M | — | ||
| Q2 24 | $269.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | — | ||
| Q3 25 | 33.8% | — | ||
| Q2 25 | 135.7% | — | ||
| Q1 25 | 21.1% | — | ||
| Q4 24 | 50.8% | — | ||
| Q3 24 | 16.5% | — | ||
| Q2 24 | 92.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 16.9% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.5% | — | ||
| Q2 24 | 12.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | 3.86× | ||
| Q3 25 | 1.05× | 2.44× | ||
| Q2 25 | 4.43× | 12.06× | ||
| Q1 25 | 0.70× | 2.50× | ||
| Q4 24 | 1.55× | 3.57× | ||
| Q3 24 | 0.63× | 1.29× | ||
| Q2 24 | 2.91× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
